| Literature DB >> 32582752 |
Richard T Agans1,2, Grace E Giles3, Michael S Goodson4, J Philip Karl5, Samantha Leyh4,6, Karen L Mumy2, Kenneth Racicot3, Jason W Soares3.
Abstract
The probiotic industry continues to grow in both usage and the diversity of products available. Scientific evidence supports clinical use of some probiotic strains for certain gastrointestinal indications. Although much less is known about the impact of probiotics in healthy populations, there is increasing consumer and scientific interest in using probiotics to promote physical and psychological health and performance. Military men and women are a unique healthy population that must maintain physical and psychological health in order to ensure mission success. In this narrative review, we examine the evidence regarding probiotics and candidate probiotics for physical and/or cognitive benefits in healthy adults within the context of potential applications for military personnel. The reviewed evidence suggests potential for certain strains to induce biophysiological changes that may offer physical and/or cognitive health and performance benefits in military populations. However, many knowledge gaps exist, effects on health and performance are generally not widespread among the strains examined, and beneficial findings are generally limited to single studies with small sample sizes. Multiple studies with the same strains and using similar endpoints are needed before definitive recommendations for use can be made. We conclude that, at present, there is not compelling scientific evidence to support the use of any particular probiotic(s) to promote physical or psychological performance in healthy military personnel. However, plausibility for physical and psychological health and performance benefits remains, and additional research is warranted. In particular, research in military cohorts would aid in assessing the value of probiotics for supporting physical and psychological health and performance under the unique demands required of these populations.Entities:
Keywords: cognition; microbiome; microbiota; nutrition; performance; physical; probiotics; warfighter
Year: 2020 PMID: 32582752 PMCID: PMC7296105 DOI: 10.3389/fnut.2020.00070
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Current questions regarding probiotic use by military personnel. Increased use of probiotics (Pbx) may be perceived to increase physical abilities including increased muscle performance (top-left), physical performance (middle-left), or endurance performance (bottom-left), or cognitive performance related to information processing (top-right) and ability to handle emotions/mood (bottom-right).
Figure 2Primary focus areas of the review. The Cognitive Domain encompasses extensive literature review of human studies associated with memory, learning, and psychological states. The Physical Domain includes physical attributes, wound healing, traumatic brain injury (TBI), and host immunity. The review was conducted to assess the current body of evidence regarding the impact of probiotics directly relevant for military personnel performance and to identify key research gaps that must be addressed to establish probiotic efficacy within this population.
Probiotic influence on physical performance in healthy individuals.
| Carbuhn et al. ( | 16 collegiate swimmers; age not reported | DB, RCT | 6 weeks | Aerobic performance: no differences | |
| Cox et al. ( | 20 elite distance runners; 7 ± 6 years | DB, RCT | 4 months | Aerobic performance: no differences | |
| Huang et al. ( | 16 amateur runners 20–40 years | DB, RCT | 6 weeks | Aerobic performance: Increased run time to exhaustion | |
| Huang et al. ( | 18 triathletes 19–24 years | DB, RCT | 4 weeks | Inflammation: improved w/probiotic | |
| Huang et al. ( | 16 triathletes 19–26 years | DB, RCT | 3 weeks | Lower body power: improved w/probiotic | |
| Ibrahim et al. ( | 21 sedentary young men; 21 ± 2 years | DB, RCT; parallel | 12 weeks | Muscle strength and power: no differences | |
| Marshall et al. ( | 32 endurance runners 23–53 years | Multi-strain probiotic | 12weeks | Aerobic fitness: no differences | |
| Shing et al. ( | 10 runners 27 ± 2 years | DB, RCT | 4 weeks | Aerobic performance: improved w/probiotic—increased run time to fatigue in the heat | |
| Toohey et al. ( | 23 collegiate athletes 20 ± 1 years | DB, RCT | 10 weeks | Lower and upper body strength: no differences | |
| Townsend et al. ( | 25 collegiate baseball players 20 ± 1 years | DB, RCT | 12 weeks | Lower body strength: no differences | |
| West et al. ( | 99 (35) cyclists 35 ± 9 years | DB, RCT | 11 weeks | Aerobic fitness: no differences |
CFU, colony forming units; w/, with; /d, per day; DB, double-blind; RCT, randomized controlled trial.
Mean ± SD; and/or range.
L. acidophilus CUL-60 1 x 10.
L. acidophilus CUL-60 2 x 10.
B., Bifidobacterium; L., Lactobacillus.
Probiotic influence on exercise-induced muscle damage in adults.
| Gepner et al. ( | 17 elite male soldiers; 20 ± 2 years | DB, RCT; parallel | 40 days | Serum inflammation markers: no differences | |
| Jager et al. ( | 29 recreationally- trained men; 21 ± 3 years | SB, not random, pre-post design | 2 weeks | Muscle soreness: improved w/ probiotic 72 h post-exercise but not 24–48 h | |
| Jager et al. ( | 15 resistance-trained men; 25 ± 4 years | DB, RCT; crossover | 3 weeks | Muscle soreness: no differences |
CaHMB, calcium β-hyroxy-β-methylbutyrate; CFU, colony forming units; w/, with; /d, per day; DB, double-blind; RCT, randomized-controlled trial; SB, single-blind.
Study population. Age is mean ± SD.
B., Bacillus; S., Streptococcus.
Impact of probiotics on GI and respiratory immunity in adults.
| Clancy et al. ( | 17 male & 10 female recreational athletes; 16–40 years | PPI | 2 x 1010 CFU/d | 4weeks | Fatigued athletes present more episodes of URIs/year and lost more activities to illness | Fatigued athletes: increased IFN-gamma production by CD4 cells Non- fatigued athletes: increased salivary IFN-gamma | No performance comparison made between treatment groups. |
| Moreira et al. ( | 123 male & 16 female trained marathon runners; 39 ± 9 years | DB, PC, RCT, parallel | Milk based | 3 monthes | No substantial difference in symptoms of atopy or asthma. | No difference between groups | No significant difference in marathon completion time between the treatment groups. |
| Tiollier et al. ( | 47 trained French Army cadets; 21 ± 0.4 years | DB, PC, RCT, parallel | Milk fermented by | 3 weeks + 5 days | No difference between groups on ERTI in incidence. | Prevented the reduction of salivary IgA after training. Immune cells did not differ between groups. | No performance comparisons made. |
| Kekkonen et al. ( | 123 male & 16 female trained marathon runners; 39 ± 9 years | DB, PC, RCT, parallel | Milk based | 3 months | Decreased number (33%) and duration (57%) of GI symptoms 2 weeks after marathon, but no effects related to URS incidence, compared with placebo | Hematological parameters within reference range for both groups. | No significant difference in marathon completion time between the treatment groups. |
| Cox et al. ( | 20 elite male runners; 20–34 years | DB, PC | Capsules containing | 4 weeks | Reduction in number (50%) of days with respiratory illness symptoms (self-reported) | Modest increase in salivary IgA and IgA1, and IFN-γ. No change in IL-4 and IL-12. | No substantial changes in running performance measures |
| West et al. ( | 64 male 35 ± 9 years & 35 female 36 ± 9 years elite competitive cyclists | DB, PC, RCT, parallel | One capsule per day containing | 11 weeks | Increase in mild GI and lower respiratory symptoms compared to placebo. | Reduced perturbations in anti-inflammatory and pro-inflammatory cytokines (IL-1RA, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α) in probiotic group. | No difference between groups in performance tests (cycle ergometry, VO2max) or exercise duration. |
| Martarelli et al. ( | 24 male recreational athletes; 32 ± 6 years | PC, RCT, parallel | Powdered mixtures of the 2 probiotic strains (1:1 | 4 weeks | NR | Increased plasma biological antioxidant potential in probiotic group. | No performance comparisons made between groups. |
| Gleeson et al. ( | 54 male & 30 female trained endurance athletes; 27 ± 11.6 years | DB, PC, RCT, parallel | Fermented milk containing | 16 weeks | Placebo group had 36% more URS and higher URTI episodes compared with probiotic group (1.2 vs. 2.1). Severity and duration of symptoms were not significantly different. | Salivary IgA concentration was higher after 8 and 16 weeks compared to placebo. No difference with IgG, IgM, or total immunoglobulin. | No performance comparisons made between groups. |
| Gleeson et al. ( | 66 trained endurance athletes; 19–28 years | DB, PC, RCT, parallel | Sachets containing | 16 weeks | No difference in URS duration between groups, no substantial difference in frequency, duration, or severity or URTI. | No difference in salivary IgA between groups. Probiotic group increased lymphocyte totals, no differences in other blood immune cells. | No performance comparisons made between groups. |
| Lamprecht et al. ( | 23 male trained athletes; 38 ± 5 years | DB, PC, RCT, parallel | Sachets containing | 14 weeks | NR | Reduced TNF concentration (25%) at rest and post-exercise, reduced exercise-induced protein oxidation (8%) compared to placebo. No difference in IL-6 production, or change in total oxidation status of lipids and malondialdehyde. | No performance comparisons made between groups. |
| Valimaki et al. ( | 125 male & 16 female trained runners; 40 years (22–69) | DB, PC, RCT, parallel | Milk based fruit drink with | 3 months | NR | Oxidized LDL lipids increased by 28% and 33% during the preparation period and decreased by 16% and 19% during the marathon run in the placebo and probiotic groups, respectively. | No performance comparisons were made. |
| West et al. ( | 241 male 35 ± 12 years & 224 female 36 ± 12 years trained runners | DB, PC, RCT, parallel | Sachets containing (i) | 164 days | A reduction in URTI episodes in probiotic groups. Symptom severity did not differ between groups. | NR | Significant decrease in activity intensity but increase in activity duration vs placebo. |
| Haywood et al. ( | 30 male elite rugby players; 20–28 years | PC, RCT, parallel | Capsules probiotics multi-species ( | 4 weeks + 4 weeks washout | Decreased incidence and duration of URTI and GI illness compared to placebo. No difference in symptom severity. | NR | No performance comparisons were made. |
| Shing et al. ( | 10 male trained runners; 27 ± 2 years | DB, RCT, PC, cross-over | Capsule providing 7.4 x 109 CFU/d of | 4 weeks + 3 weeks washout | Small reduction in symptoms of GI discomfort compared to placebo | A small-to-moderate reduction in urine lactulose:rhamnose. Significantly lower plasma LPS/GI permeability in probiotic group. No significant difference with IL-6, IL-10, and IL-1ra compared to placebo. No significant differences with hematological variables or urinary claudin-3 pre- vs. post- exercise. | Significant increase in running time to fatigue in high temperatures compared to placebo |
| O'Brien et al. ( | 67 recreational but untrained subjects; 18–35 years | PC, PPI | Fermented kefir beverage containing undefined | 15 weeks | NR | Plasma c-reactive protein (CRP) increased due to exercise, but no difference due to probiotic intervention. | No performance comparison made with respect to probiotic. |
| Gill et al. ( | 8 male trained adults; 26 ± 6 years | B, RCT, PC, cross-over | 1 weeks | NR | No significant changes in resting circulatory endotoxin concentration or plasma cytokine profile compared to placebo. Relative to pre-EHS concentrations, higher plasma concentrations of endotoxin TNF-α were observed compared to placebo. | No performance comparisons were made due to probiotic intervention. | |
| Gleeson et al. ( | 156 male, 112 female recreational athletes; 21 ± 3 years | DB, PC, RCT, parallel | Fermented milk containing | 16 weeks | No differences related to URS, number of episodes, total symptom score, or episode duration. | Decreased IgG-specific antibodies for cytomegalovirus (CMV) and Epstein-Barr virus compared with baseline of probiotic group. No differences in immune cell counts. | No performance comparisons were made due to probiotic intervention |
| Michalickova et al. ( | 36 male, 14 female elite athletes; 18–28 years | DB, PC, RCT | Capsules containing | 14 weeks | Decrease in URTI episode duration and number of symptoms compared to placebo. No difference in symptom severity and incidence of URTI between groups. | No significant changes in leukocyte abundance, TBF-β serum levels, IL-10 from peripheral blood mononuclear cells (PBMCs), IFN-γ level from PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant. | No performance comparisons were made due to probiotic intervention |
| Roberts et al. ( | 25 male, 5 female recreational triathletes; 35 ± 1 years | DB, PC, RCT | Capsule containing | 12 weeks | GI symptom episodes were lower in the probiotic + FOS group at each month of prerace training, and the severity of GI symptoms was lower | Reduction in plasma endotoxin levels at pre-race and 6 days post-race, as well as for IgG levels recorded 6 d postrace. No significant difference in GI permeability between groups Lactose:Mannitol increased marginally from baseline to pre-race and 6 days post-race with probiotic +antioxidant. | Non-significant trend of faster overall time to finish in probiotic groups. |
| Strasser et al. ( | 13 male, 16 female trained athletes; 22–30 years | DB, PC, RCT, parallel | Sachet containing 1 x 1010 CFU multispecies | 3 months | Incidence of URTI decreased for both groups over 12 weeks, yet fewer probiotic treated subjects had URTI after 12 weeks (5 vs 8). | After the acute exercise, probiotic group lost less tryptophan vs. placebo. Female participants had higher degradation of tryptophan compared with male participants. | Significant increase in training hours per week and decreased resting energy expenditure compared to placebo. |
| Marshall et al. ( | 24 male, 6 female trained endurance athletes; 23–53 years | RIM, parallel | Capsules with or without glutamine contained 1 x 1010 CFU/d, | 12 weeks | NR | Blood eHSP72 was not different between nutritional groups (probiotic with or without glutamine). | Time to race completion was not different between groups. |
| Michalickova et al. ( | 22 male elite athletes; 20–24 years | DB, PC, RCT, parallel | Capsules containing | 14 weeks | NR | Decreased malondialdehyde (MDA), superoxide dismutase activity (SOD) serum paraoxonase (PON1) compared to placebo. | No performance comparisons were made due to probiotic administration. |
| Carbuhn et al. ( | 20 female elite swimmers; 19–23 years | DB, PC, RCT, parallel | Capsules containing | 6 weeks | Mild improvement in RESTQ52-sport weekly self-regulation scores of stress. No URTI or URS measures. | No difference in panel of systemic inflammatory markers. Endotoxin (LPS) and LPS-binding protein (LPB) were not statistically different between groups. Small but significant decrease in the systemic cytokine marker IL-1ra within the probiotic group at mid-training found. | No significant difference between supplemented groups |
| Komano et al. ( | 51 male recreational athletes; 19–21 years | DB, PC, RCT, parallel | Capsules containing heat killed | 13 days | Significant decrease in some respiratory symptoms and cumulative days of URTI, decreased fatigue accumulation compared to placebo. | CD86 as maturation marker on dendritic cell activity was significantly increased in the probiotic group at day 14. | No difference between training time between groups. No performance comparisons were made due to probiotic intervention. |
Updated and adapted from AR 40-501 (.
Mean ± SD; and/or range.
Strain not reported.
Species/strain not reported.
B., Bifidobacterium; C., Clostridium; E., Enterococcus; L., Lactobacillus, S., Streptococcus.
Probiotic influence on markers of gastrointestinal barrier integrity in healthy adults.
| Carbuhn et al. ( | 16 female collegiate swimmers; age not reported | DB, RCT; parallel | 6 weeks | Inflammation: no differences | |
| Gill et al. ( | 8 endurance trained male runners; 26 ± 6 years | DB, RCT; crossover | 7 days | Plasma endotoxin (post-exercise): worsened w/ probiotic | |
| Lamprecht et al. ( | 23 endurance trained men; 38 ± 4 years | DB, RCT; parallel | 14 weeks | GI permeability (indirectly measured): improved w/ probiotic | |
| Roberts et al. ( | 20 recreationally active adults; 35 ± 2 years | DB, RCT; parallel | 13 weeks | Small intestinal permeability: improved w/ probiotic | |
| Shing et al. ( | 10 male runners; 27 ± 2 years | DB, RCT; crossover | 4 weeks | Gastroduodenal permeability: no differences | |
| Endo et al. ( | 29 chronic aspirin and omeprazole users + iron deficiency anemia; 72 ± 7 years | DB, RCT; parallel | 3 months | Mucosal damage, small intestine: improved w/ probiotic | |
| Gotteland et al. ( | 16 healthy adults; 23 ± 4 years | DB, RCT; crossover | 5 days | Gastroduodenal permeability: improved w/ probiotic | |
| Krumbeck et al. ( | 94 obese adults; 44 ± 11 years | DB, RCT; parallel | 3 weeks | GI permeability: no differences | |
CFU, colony forming units; DB, double-blind; FOS, fructo-oligosaccharides; GI, gastrointestinal; GOS, galacto-oligosaccharide; LPS, lipopolysaccharide; NSAID, non-steroidal anti-inflammatory drug; RCT, randomized-controlled trial; w/ = with.
Strain not reported.
Mean ± SD and/or range.
B., Bifidobacterium; C., Clostridium; E., Enterococcus; L., Lactobacillus, S., Streptococcus.
Categorization of cognitive tasks.
| Motor Speed and Information Processing | Cogstate Detection Test |
| Attention | Rapid Visual Information Processing Task |
| Learning and Memory | Cogstate Groton Maze Final Recall |
| Cognitive Control | Attention Switching Task |
Categorization of mood and emotion scales.
| Depression | Beck Depression Inventory |
| Anxiety | Beck Anxiety Inventory |
| Stress | Depression, Anxiety and Stress Scale |
| Discrete Mood Scales | Bond Lader Mood Scales |
| Emotion Regulation | Coping Checklist |
Probiotic influence on cognition in healthy individuals.
| Allen et al. ( | 22 healthy adults, 25.5 ± 1.2 years | DB, RM | 4 weeks | Learning: Probiotic improved | |
| Benton et al. ( | 126 healthy adults, 48–79 61.8 ± 7.3 years | DB, RCT | 65 mL | 20 days | Short-term memory: Probiotic impaired after 20 (not 10) days |
| Chong et al. ( | 111stressed adults, 18–60 years | DB, RCT | 12 weeks | Social Emotion Cognition: Probiotic improved speed Verbal learning and memory: Probiotic improved speed | |
| Chung et al. ( | 36 healthy older adults, 60–75 65.0 ± 1.1 years | DB, RCT | 12 weeks | Sustained Attention: 1,000 mg probiotic improved | |
| Kelly et al. ( | 29 healthy adults, 20–33 24.6 ± 0.8 years | DB, RCT, Cross-over | 4 weeks | Memory: No differences | |
| Lew et al. ( | 103 stressed adults, 18–60 years | DB, RCT | 12 weeks | Social emotional cognition: Probiotic improved speed | |
| Papalini et al. ( | 58 healthy adults, 18–40 years | DB, RCT | Multispecies | 4 weeks | Emotional reactivity: No differences |
CFU, colony forming units; DB, double blind; RM, repeated; M, measures; RCT, randomized controlled trial.
Strain not reported.
Mean ± SD and/or range
B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, L. lactis W19, and L. lactis W58.
B, Bifidobacterium; L, Lactobacillus.
Probiotic influence on mood in healthy individuals.
| Allen et al. ( | 22 healthy adults, 25.5 ± 1.2 years | DB, RM | 4 weeks | Stress: Probiotic reduced daily stress | |
| Benton et al. ( | 126 healthy adults, 48–79 61.8 ± 7.3 years | DB, RCT | 65 mL | ~3 weeks | Elated/depressed: Probiotic reduced depression in lowest baseline tertile for depression only |
| Chong et al. ( | 111 stressed adults, 18–60 years | DB, RCT | 12 weeks | Stress: Probiotic reduced | |
| Chung et al. ( | 36 healthy older adults, 60–75 years | DB, RCT | 12 weeks | Depression: No differences | |
| Kelly et al. ( | 29 healthy adults, 20–33 24.6 ± 0.8 years | DB, RCT, Cross-Over | 4 weeks | Depression: No differences | |
| Lew et al. ( | 103 stressed adults, 18–60 years | DB, RCT | 12 weeks | Stress [DASS]: Probiotic reduced | |
| Marotta et al. ( | 38 healthy adults, 19–33 22.00 ± 3.02 years | DB, RCT | 6 weeks | Depression Sensitivity: No differences total score; Probiotic increased acceptance | |
| Messaoudi et al. ( | 55 healthy adults, 30–60 Probiotic: 42.4 ± 7.5 years Placebo: 43.2 ± 8.5 years | DB, RCT | 4 weeks | Anxiety: Probiotic reduced anxiety | |
| Messaoudi et al. ( | 25 healthy adults, 30–60 years | DB, RCT | 4 weeks | Stress: Probiotic reduced | |
| Noorwali et al. ( | 60 healthy adults, 18–40 years | DB, RCT | 6 weeks | Anxiety: No differences | |
| Owen et al. ( | 50 healthy adults, 19–38 32.2 ± 3.8 years | DB, RCT | 6 weeks | Anxiety: Probiotic reduced | |
| Papalini et al. ( | 58 healthy adults, 18–40 years | DB, RCT | Multispecies | 4 weeks | Depression: No differences |
| Steenbergen et al. ( | 40 healthy adults, Probiotic: 20.2 ± 2.4 yr Placebo: 19.7 ± 1.7 yr | DB, RCT | Multispecies probiotic (>2.5 x 109 CFU/g) vs. placebo powder | 4 weeks | Cognitive reactivity to sad mood: Probiotic reduced |
| Wang et al. ( | 40 healthy adults, 18–50 years | DB, RCT | 4 weeks | Distress: No differences |
BDI, Beck Depression Inventory; CFU, colony forming unit; NR, not reported; DASS, Depression, Anxiety and Stress Scale (DASS-42); PSS, Perceived Stress Scale; POMS, Profile of Mood States; HSCL-90, Hopkins Symptom Checklist-90; HADS-D, Hospital Anxiety and Depression Scale-Depression, DB, double blind, RM, repeated measures, RCT, randomized controlled trial, TB, triple blind.
Strain not reported.
Mean±SD and/or range.
Secondary analysis of Messaoudi et al. (.
Conference Proceedings.
B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, L. lactis (W19 and W58).
B, Bifidobacterium; L, Lactobacillus.
Probiotic influence on wound healing in adults.
| Blanchet-Rethore et al. ( | 21 adults w/ atopic dermatitis and carrying | NB; non-random | Heat-treated | 3 weeks | |
| Gueniche et al. ( | 75 men/women w/ atopic dermatitis; 6–70 years | DB, RCT; parallel | Lotion containing 5% | 30 days | Lesion severity: Improved w/ probiotic |
| Gueniche et al. ( | 62 women w/ sensitive skin; 32 ± 12 years | DB, RCT; parallel | 8 weeks | TEWL: improved w/ probiotic | |
| Lee et al. ( | 110 women w/ dry skin; 49 ± 4 years | DB, RCT; parallel | 12 weeks | TEWL, face: improved/ probiotic | |
| Mohseni et al. ( | 60 adults w/ diabetic foot ulcer; 60 ± 10 years | DB, RCT; parallel | 12 weeks | Wound healing: improved w/ probiotic | |
| Ogawa et al. ( | 118 adults w/ elevated TEWL; 41 ± 8 years | DB, RCT; parallel | Heat-killed | 12 weeks | TEWL, forearm: no differences |
| Peral et al. ( | 80 adult burn patients; 18–55 year | 10 days | Wound healing: improved by probiotics in infected 3rd degree burns, but not infected 2nd degree burns or non-infected 3rd degree burns. | ||
| Peral et al. ( | 34 adults w/ chronic leg ulcers; 40–70 years | NB, non-random;pre-post trial | 10–30 days | Wound healing: Total healing after 30 days in 43% of diabetics and 50% of non-diabetics. |
CFU, colony forming units; DB, double-blind; NB, not blinded; RCT, randomized controlled trial; TEWL, transepidermal water loss; w/ with.
Population. Age is mean ± SD or range.
Strain(s) not identified.
Blinding not described.
B, Bifidobacterium; L, Lactobacillus.
Summary of probiotics used in Physical and Cognitive performance studies.
Probiotics administered both alone and as part of a cocktail;
probiotics administered solely in a cocktail.
Strain not reported.
B, Bifidobacterium; C, Clostridium; E, Escherichia; L, Lactobacillus, S., Saccharomyces.